Be the first to like this
1) ADCT-301, a CD25 targeting ADC from ADC Therapeutics utilising PBD payload and HuMax technology.
2) PCA062, a p-Cadherin targeting ADC from
3) We were interested to see the re-introduction of ImmunoGen’s IMGN-901 into clinical trials with two new phase II trials added this month, for leukemia and childhood cancers.
In addition we have been adding a significant number of immunotoxins, including denileukin diftitox (ONTAK®), Moxetumomab pasudotox, LMB-2, naptumomab estafenatox, VB4-845, D2C7-IT and SS1P.
Read June’s Digest in Full